These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12851773)

  • 21. Tolterodine once-daily in treatment of the overactive bladder.
    Peters KM; Huang RR
    Urology; 2001 Nov; 58(5):829-32. PubMed ID: 11711378
    [No Abstract]   [Full Text] [Related]  

  • 22. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
    Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
    J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.
    Jonas U; Höfner K; Madersbacher H; Holmdahl TH
    World J Urol; 1997; 15(2):144-51. PubMed ID: 9144906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolterodine: a safe and effective treatment for older patients with overactive bladder.
    Malone-Lee JG; Walsh JB; Maugourd MF
    J Am Geriatr Soc; 2001 Jun; 49(6):700-5. PubMed ID: 11454106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.
    Harvey MA; Baker K; Wells GA
    Am J Obstet Gynecol; 2001 Jul; 185(1):56-61. PubMed ID: 11483904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolterodine: a clinical review.
    Crandall C
    J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Solifenacin versus tolterodine--a head-to-head study: finally! But not final?
    Staskin DR; Dmochowski RR; Wein AJ
    Curr Urol Rep; 2005 Nov; 6(6):403-4. PubMed ID: 16238911
    [No Abstract]   [Full Text] [Related]  

  • 29. Tolterodine-associated acute mixed liver injury.
    Schlienger RG; Keller MJ; Krähenbühl S
    Ann Pharmacother; 2002 May; 36(5):817-9. PubMed ID: 11978158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone.
    Kreder KJ; Brubaker L; Mainprize T
    BJU Int; 2003 Sep; 92(4):418-21. PubMed ID: 12930432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolterodine use for symptoms of overactive bladder.
    Ruscin JM; Morgenstern NE
    Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin.
    Rovner ES; Wein AJ
    BJU Int; 2000 Oct; 86 Suppl 2():44-53; discussion 53-4. PubMed ID: 11501617
    [No Abstract]   [Full Text] [Related]  

  • 35. Urinary incontinence management: new questions from old assumptions.
    DuBeau CE
    J Am Geriatr Soc; 2001 Jun; 49(6):829-30. PubMed ID: 11454125
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
    Agarwal A; Dhiraaj S; Singhal V; Kapoor R; Tandon M
    Br J Anaesth; 2006 Mar; 96(3):377-80. PubMed ID: 16415311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
    Jonas U; Rackley RR
    Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
    [No Abstract]   [Full Text] [Related]  

  • 38. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity--a comment.
    Short DD
    Pharmacotherapy; 1999 Oct; 19(10):1188. PubMed ID: 10512072
    [No Abstract]   [Full Text] [Related]  

  • 39. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.
    Burgio KL; Kraus SR; Menefee S; Borello-France D; Corton M; Johnson HW; Mallett V; Norton P; FitzGerald MP; Dandreo KJ; Richter HE; Rozanski T; Albo M; Zyczynski HM; Lemack GE; Chai TC; Khandwala S; Baker J; Brubaker L; Stoddard AM; Goode PS; Nielsen-Omeis B; Nager CW; Kenton K; Tennstedt SL; Kusek JW; Chang TD; Nyberg LM; Steers W;
    Ann Intern Med; 2008 Aug; 149(3):161-9. PubMed ID: 18678843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.